Taysha Gene Therapies filed an 8-K on November 4, 2025, detailing material amendments to its At-The-Market (ATM) equity offering facility concurrent with reporting third quarter 2025 financial results.
Capital Raising & Financial Structure: The Company executed an amendment to its Sales Agreement, immediately terminating Leerink Partners LLC as a sales agent. The remaining agents, Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC, will facilitate an increased aggregate offering capacity up to $212 million. The offering utilizes an automatic shelf registration (Form S-3ASR), and Tays
...